Neon Therapeutics Provides Business Update and Outlook for 2019

MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference

TARIS Appoints Tony Kingsley as President and Chief Executive Officer

Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer

Pliant Therapeutics Appoints Keith Cummings as Chief Financial Officer and Eduard Gorina as Vice President, Clinical Development

Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809; Development in Orphan Lung Disease Idiopathic Pulmonary Fibrosis Planned

REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019

Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria

Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference

GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference

Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019

MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019

Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019

Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer

Pliant Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

Foundation Medicine Announces Regulatory Approval of FoundationOne®CDx in Japan

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration

Relay Therapeutics Secures $400 Million in Series C Financing

Editas Medicine Announces Transition of Chief Financial Officer

CytomX Therapeutics Announces Changes to its Board of Directors

Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson's Disease

Jeff Jonker Joins Ambys Medicines as President and CEO

Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture

MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients

Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Editas Medicine Names Cynthia Collins to Board of Directors

Frank S. Czerwiec, M.D., Ph.D. Joins Goldfinch Bio as Chief Medical Officer

Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson's Disease

Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering

Ablexis Announces Licensing Agreement with Allogene Therapeutics

Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery

Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome

Global Blood Therapeutics Announces Proposed Public Offering of Common Stock

MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference

Relay Therapeutics Strengthens R&D Leadership Team With Key Additions In Chemistry And Pharmaceutical Development

Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer

GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile

GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)

Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)

Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor